The integrase inhibitors market is estimated to be valued at US$ 29.34 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Integrase inhibitors are antiretroviral drugs (ARVs) used for the treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). They block integrase, an HIV enzyme that inserts viral DNA into the DNA of infected immune cells. Products such as Isentress, Tivicay, and Vitekta are commonly prescribed integrase inhibitors. Their high effectiveness against HIV makes them a popular treatment option.
Market Dynamics:
The integrase inhibitors market is expected to gain significant growth due to the rising prevalence of HIV/AIDS globally. According to UNAIDS, around 38 million people were reported to be living with HIV in 2020 worldwide. Moreover, integrase inhibitors are gaining popularity over other classes of ARVs such as protease inhibitors due to better efficacy and tolerability. They have fewer side effects and drug interactions, making them preferred first-line treatment regimen. Another major driver is the expansion of integrase inhibitor product lines by key players. This enables treatment of a larger patient pool and drives the market growth.
SWOT Analysis
Strength: Integrase Inhibitors are effective against HIV and have minimal side effects. They inhibit a crucial step in the HIV replication cycle. Moreover, they are available in once-daily pills which increases patient adherence to treatment.
Weakness: Integrase Inhibitors are very expensive and unaffordable for people in low and middle-income countries. Additionally, there is a risk of developing resistance to these drugs if not taken correctly.
Opportunity: Growing HIV prevalence rates globally is increasing the patient pool for Integrase Inhibitors. Additionally, development of low-cost generic versions of these drugs provides an opportunity to cater to emerging markets.
Threats: Alternative treatment options such as entry or fusion inhibitors pose competition to Integrase Inhibitors. Additionally, development of a vaccine against HIV would significantly reduce the market for anti-retroviral drugs.
Key Takeaways
Global Integrase Inhibitors Market Size is expected to witness high growth, exhibiting CAGR of 3.9% over the forecast period, due to increasing prevalence of HIV globally. The market size is projected to reach US$ 29.34 Bn by 2023.
Regional analysis: North America dominates the global market currently due to high healthcare spending and robust payor coverage for HIV treatment. However, the Asia Pacific region is expected to grow at the fastest pace due to large patient population and growing access to healthcare in emerging countries.
Key players: Key players operating in the Integrase Inhibitors market are Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd. These companies are focused on developing low-cost generic versions and fixed-dose combinations to expand access in developing markets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it